REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)

NCT07599904 | Not Yet Recruiting

• 1 other identifier: RECANOVA Registry
• Study Type: observational
• Target: 1,500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Post-Market Registry

Conditions

Acute Ischemic Stroke

Outcome Measures

Primary Outcomes (3)

• Evaluate device safety

  Incidence of Safety Events of Interest through 90-day follow-up

  From Day 0 to 90 days post-procedure

• Evaluate device performance

  Reperfusion defined as eTICI ≥2b50; ≥2b67; ≥2c; =3 at end of procedure.

  Day 0 - end of index stroke procedure

• Evaluate device effectiveness

  Functional independence as measured by modified Rankin Scale (mRS) score ≤ 2 at 90-day follow up (mRS scores range from 0 \[no symptoms\] to 6 \[death\]).

  From Day 0 to 90 days post-procedure

Interventions

Device: Mechanical Thrombectomy PROCEDURE

Index stroke procedure and follow-up visits up to 90 days post index procedure

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients requiring treatment with Medtronic Neurovascular commercially available devices used during the treatment of acute ischemic stroke (AIS)

You may qualify if:

• Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements.
• Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\* during treatment for acute ischemic stroke.
• Participant is 18 years of age or older.

You may not qualify if:

• Participant who may be unable to complete follow-up within the registry.
• Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.
• Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion.

Sponsors & Collaborators

• Medtronic Neurovascular Clinical Affairs: lead

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Stephanie Salisbury

CONTACT

612-979-7251; rs.recanovaregistry@medtronic.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 90 Days
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2026
• First Posted: May 20, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): July 1, 2031
• Study Completion (Estimated): July 1, 2031
• Last Updated: May 20, 2026

Record last verified: 2026-05